Explore groundbreaking advancements in mental health treatments, including novel drugs for depression, anxiety, schizophrenia, and bipolar disorder. Discover personalized medicine approaches, the integration of artificial intelligence in therapy, and the development of fast-acting antidepressants and psychedelic-assisted therapies. This covers new molecules targeting specific neurotransmitters, innovative antipsychotics, and improved pharmacotherapy protocols for psychiatric conditions.
Diseñado para eludir el metabolismo hepático de primer paso
(+2)
In Phase 2/3 development, GlyphAllo is a GABA neurosteroid that promises a rapid onset of antidepressant and anxiolytic action. Its mechanism, different from benzodiazepines, could avoid dependence, offering a promising option for depression with anxiety.
Nuevo antipsicótico atípico aprobado por la FDA
(+4)
Approved by the FDA in February 2026, Bysanti is a new atypical antipsychotic that offers a novel therapeutic option. Its mechanism of action, with strong affinity for alpha-1 adrenergic receptors, distinguishes it from other antipsychotics.
This innovation represents a crucial advance for patients with treatment-resistant depression, offering rapid symptom relief in hours, not weeks. Its approval as monotherapy in January 2025 allows its use without a concomitant oral antidepressant, simplifying treatment.
Es una NDSRI (noradrenalina + dopamina + serotonina)
(+4)
This drug is under priority review by the FDA in 2026 and represents a 'first-in-class' option for ADHD. Its mechanism of action as a norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI) could transform the approach to ADHD in adults.
Innovador enfoque terapéutico para la esquizofrenia
(+4)
Approved by the FDA in September 2024, Cobenfy is a new antipsychotic that stands out for offering fewer side effects compared to traditional antipsychotics. This improves treatment adherence in patients with schizophrenia, a critical factor for therapeutic success.
All the rankings you can imagine
Thousands of verified votes to discover the best. Your vote here counts
Designación de terapia innovadora de la FDA
(+4)
With Breakthrough Therapy designation by the FDA and in Phase 3 clinical trials, MM120 represents a paradigm shift in anxiety treatment. A single dose has shown significant and sustained improvements in generalized anxiety disorder, with effects lasting weeks or months.
Designación de vía rápida de la FDA para el tratamiento agudo del TCA
(+4)
This medication, in Phase 3 clinical trials, offers an innovative approach to social anxiety disorder. Administered as a nasal spray, it acts directly on the brain regions involved in anxiety, promising a rapid onset of action and fewer systemic side effects.
Estudiadas para depresión resistente
(+4)
The FDA has accelerated research and granted national priority vouchers in April 2026 to these substances, underscoring their potential. They represent a promising frontier in the treatment of severe and resistant mental disorders, with the capacity to address the mental health crisis.
Primera formulación subcutánea de risperidona de acción prolongada
(+4)
Approved in October 2025, this risperidone formulation offers an extended-release option administered by subcutaneous injection. Its approval as monotherapy or adjunctive therapy for bipolar I disorder can significantly improve treatment adherence, a common challenge in this condition.